Cytokinetics, Incorporated(CYTK)Earnings, Financials & Key RatiosCytokinetics, Incorporated (CYTK) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the rapid depletion of cash reserves from $882.2 million to $129.8 million in a single quarter suggests an urgent need for dilutive financing to sustain operations ahead of potential regulatory milestones.
Cytokinetics, Incorporated (CYTK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Cytokinetics, Incorporated (CYTK) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.67vs $1.67+0.0% | $19Mvs $9M+127.2% |
| Q1 2026 | Feb 24, 2026 | $1.50vs $1.48-1.4% | $18Mvs $7M+156.3% |
| Q4 2025 | Nov 5, 2025 | $1.54vs $1.59+3.1% | $2Mvs $8M-75.9% |
| Q3 2025 | Aug 7, 2025 | $1.12vs $1.34+16.4% | $67Mvs $2M+3131.1% |
Recent stock market news and headlines for Cytokinetics, Incorporated (CYTK)
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment.
Key metrics vs top competitors for Cytokinetics, Incorporated (CYTK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $85.56 | $10.54B | -13.08 | 376.56% | -891.6% | — | — | |
| $545.36 | $12.57B | -42.44 | 432.05% | -27.32% | -50.15% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Cytokinetics, Incorporated (CYTK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Cytokinetics, Incorporated (CYTK) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
May 5, 2026·SEC
Feb 24, 2026·SEC
Get notified when CYTK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cytokinetics, Incorporated (CYTK) stock FAQ — growth, dividends, profitability & financials explained
Cytokinetics, Incorporated (CYTK) reported $105.8M in revenue for fiscal year 2025. This represents a 829% increase from $11.4M in 2002.
Cytokinetics, Incorporated (CYTK) grew revenue by 376.6% over the past year. This is strong growth.
Cytokinetics, Incorporated (CYTK) reported a net loss of $829.6M for fiscal year 2025.
Cytokinetics, Incorporated (CYTK) had negative free cash flow of $548.9M in fiscal year 2025, likely due to heavy capital investments.
